Orchestra BioMed announced the patent estate related to AVIM Therapy has reached 110 patents worldwide. The most recent patent was issued today, April 30, 2024. “We are very proud of the extensive intellectual property portfolio we have amassed related to our lead program, AVIM therapy, which we’re actively evaluating for the treatment of hypertension in pacemaker-indicated patients in the BACKBEAT global pivotal study alongside our colleagues at Medtronic,” commented David Hochman, chief executive officer, chairman and founder of Orchestra Biomed. “We have vigorously pursued strong IP protection for AVIM therapy and continue to enhance the portfolio with 15 new patents granted for the treatment of hypertension since becoming a public company in January 2023. The depth and breadth of this patent estate represent the culmination of over a decade of work to bring a truly innovative therapeutic option to patients who deserve improved clinical outcomes and reflects an essential element of the value Orchestra BioMed provides in our strategic collaboration with Medtronic.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OBIO:
- Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents
- Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
- Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors
- Orchestra BioMed appoints David Pacitti to board of directors
- Orchestra BioMed announces presentations on Virtue SAB, AVIM therapy